Giant Cell Arteritis: Headache, Jaw Pain, and Vision Symptoms You Should Not Ignore

Giant cell arteritis is a time-sensitive vasculitis

A new, persistent headache in someone over 50 is common enough to be dismissed as tension, sinus pressure, or aging. In giant cell arteritis, however, that headache can signal inflammation of medium and large arteries supplying the scalp, jaw, eyes, and brain. The clinical stakes are unusually high: untreated disease can cause irreversible vision loss, while early glucocorticoids markedly reduce that risk. For patients and clinicians, the challenge is recognizing the pattern before an ischemic complication declares itself.

Why the headache, jaw pain, and eye symptoms cluster together

GCA is granulomatous vasculitis, meaning immune cells invade the arterial wall and create swelling, narrowing, and sometimes occlusion. The superficial temporal artery is visible and biopsy-accessible, but the disease is systemic; the aorta and its branches may also be involved. Headache occurs when inflamed scalp arteries and surrounding tissues become tender. Jaw claudication is different from temporomandibular joint soreness: chewing repeatedly demands blood flow from arteries that are narrowed, so pain or fatigue builds with use and improves with rest.

Vision symptoms arise when blood supply to the optic nerve or retina is compromised. Patients may describe transient dimming, double vision, episodes of a curtain coming over one eye, or sudden painless visual loss. These are not “migraine until proven otherwise” in an older adult with inflammatory features.

Clues that should raise suspicion

The 2022 ACR/EULAR classification criteria assign weight to age 50 or older, new temporal headache, abnormal temporal artery examination, elevated inflammatory markers, positive temporal artery biopsy or ultrasound halo sign, and large-vessel imaging findings. Classification criteria are not diagnostic rules, but they reflect the features that consistently separate GCA from mimics in research cohorts.

Clinically useful warning features

Warning features include:

• New localized headache or scalp tenderness, especially pain with combing hair or lying on a pillow.
• Jaw or tongue claudication with chewing, speaking, or prolonged use.
• Transient or persistent vision symptoms, including double vision.
• Constitutional symptoms such as fever, weight loss, fatigue, or night sweats.
• Polymyalgia rheumatica symptoms: bilateral shoulder or hip girdle aching and morning stiffness.

Laboratory tests support the impression but do not replace it. Erythrocyte sedimentation rate and C-reactive protein are usually elevated, and anemia or thrombocytosis may appear, yet a small minority of patients have modest markers. Conversely, high inflammatory markers are nonspecific. The diagnosis rests on probability: symptoms, exam, labs, and vascular imaging or biopsy interpreted together.

What current guidelines say about evaluation

The 2021 American College of Rheumatology/Vasculitis Foundation guideline emphasizes rapid treatment when clinical suspicion is high, because diagnostic testing should not delay protection of vision. Temporal artery biopsy remains highly specific and is ideally obtained within two weeks of starting glucocorticoids, though positive findings can persist longer. The guideline conditionally favors biopsy over ultrasound in many United States settings, largely because ultrasound accuracy depends on immediate access and operator expertise.

EULAR imaging recommendations give ultrasound a larger role, particularly in centers with trained vascular sonographers. The “halo sign” represents arterial wall edema. CT angiography, MR angiography, or PET-CT may be used when large-vessel involvement is suspected, such as limb claudication, bruits, asymmetric blood pressures, or unexplained systemic inflammation.

Treatment is a balance between speed and stewardship

High-dose glucocorticoids remain the initial therapy because they suppress arterial inflammation quickly. If there are threatened or established visual symptoms, many clinicians use intravenous methylprednisolone before transitioning to oral prednisone; without cranial ischemia, high-dose oral therapy is typical. The reasoning is straightforward: the short-term harm of undertreating active cranial vasculitis outweighs the predictable steroid toxicity, at least at presentation.

Stewardship begins immediately afterward. Prolonged prednisone causes infection risk, hyperglycemia, hypertension, osteoporosis, cataracts, mood change, and myopathy. Tapering too fast risks relapse; tapering too slowly creates avoidable harm. This is where rheumatology management becomes longitudinal rather than episodic.

Tocilizumab and steroid-sparing strategy

The GiACTA trial, published in the New England Journal of Medicine in 2017, showed that weekly or every-other-week tocilizumab plus a 26-week prednisone taper achieved sustained remission more often than prednisone taper alone. Tocilizumab blocks the interleukin-6 receptor, a pathway central to the acute-phase response. The ACR/VF guideline conditionally recommends tocilizumab with glucocorticoids for many newly diagnosed patients, especially those at high risk for steroid toxicity or relapse.

The tradeoff is monitoring. Because IL-6 blockade lowers CRP and fever responses, relapse may be clinically subtle. Clinicians must listen carefully for recurrent cranial symptoms and monitor vascular disease when indicated, rather than relying only on a normal CRP.

A common misconception: “The biopsy was negative, so it is not GCA”

Temporal artery biopsy can miss disease because inflammation is segmental, producing “skip lesions.” A negative biopsy lowers probability but does not erase a convincing clinical picture, particularly if imaging, symptoms, and inflammatory markers align. Conversely, empiric steroids should not become a permanent diagnosis without reassessment. The best practice is iterative: revisit the history, examine temporal and limb pulses, review pathology length and quality, and ask whether large-vessel imaging is needed.

An illustrative clinical scenario

Consider a 73-year-old with two weeks of new right temporal headache, scalp tenderness, and jaw fatigue halfway through meals. CRP is markedly elevated, and she reports one ten-minute episode of gray vision in the right eye. Even before biopsy results, this constellation justifies treating as high-probability GCA while arranging ophthalmologic assessment and vascular confirmation. The jaw symptom matters because it indicates exertional ischemia, not just pain sensitivity.

What the evidence supports now

GCA remains a clinical diagnosis supported by labs, biopsy, and imaging. Evidence supports immediate glucocorticoids when suspicion is high and earlier steroid-sparing therapy for selected patients. Uncertainty persists around optimal imaging surveillance, taper duration, and individualized relapse prediction across cranial and large-vessel phenotypes.